3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
4
Ureteral Neoplasms
3
Urologic Neoplasms
2
Urethral Neoplasms
2
Carcinoma, Transitional Cell
2
Urothelial Cancer
1
Metastatic Urothelial Cancer
1
Interventions
enfortumab vedotin
2
pembrolizumab
1
avelumab
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has announcements
×
Urologic Neoplasms
×
enfortumab vedotin
×
Clear all
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA
NCT03219333
2024-08-27
EV-201
Astellas Pharma Inc
Phase 2
Completed
219 enrolled
32 charts
2 FDA